Weill-Engerer Sébastien, David Jean Philippe, Sazdovitch Véronique, Liere Philippe, Schumacher Michael, Delacourte André, Baulieu Etienne Emile, Akwa Yvette
INSERM U488, Stéroides et Système Nerveux, 80 Rue du Général Leclerc, 94276, Le Kremlin-Bicêtre, France.
Brain Res. 2003 Apr 18;969(1-2):117-25. doi: 10.1016/s0006-8993(03)02288-1.
The description of dehydroepiandrosterone (DHEA) as a neuroactive neurosteroid has raised the important question of whether the steroid itself and/or its metabolite(s) are active in the brain. Classical transformations of DHEA in brain and peripheral tissues include its conversion to testosterone and estradiol. In the human brain, the metabolism of DHEA to other metabolites is still poorly understood, particularly in aging people and Alzheimer's patients. The present study describes the in vitro transformation of DHEA into 7alpha-hydroxy-DHEA and Delta5-androstene-3beta,17beta-diol, for the first time in the aging brain of patients with Alzheimer's disease in comparison with non-demented controls. Formal identification of DHEA metabolites is provided by gas chromatography-mass spectrometry, thus indicating the presence of NADPH-dependent 7alpha-hydroxylase and 17beta-hydroxysteroid oxidoreductase activities. Under our experimental conditions, the synthesis of 7alpha-hydroxy-DHEA and Delta5-androstene-3beta,17beta-diol occurs in the frontal cortex, hippocampus, amygdala, cerebellum and striatum of both Alzheimer's patients and non-demented controls. In both groups of patients, the pattern of DHEA metabolism is similar, but significant higher synthesis of 7alpha-hydroxy-DHEA in the frontal cortex and Delta5-androstene-3beta,17beta-diol in the cerebellum and striatum were observed compared with those in other brain regions. In addition, a trend toward a significant negative correlation is found between the density of cortical amyloid deposits and the amount of 7alpha-hydroxy-DHEA formed in the frontal cortex and that of Delta5-androstene-3beta,17beta-diol in the hippocampus. Therefore, the biosynthesis of 7alpha-hydroxy-DHEA and/or Delta5-androstene-3beta,17beta-diol is likely to regulate DHEA cerebral concentrations and may contribute to the control of DHEA activity in the aging brain including in Alzheimer's disease.
将脱氢表雄酮(DHEA)描述为一种具有神经活性的神经甾体引发了一个重要问题,即该甾体本身和/或其代谢产物在大脑中是否具有活性。DHEA在大脑和外周组织中的经典转化包括其转化为睾酮和雌二醇。在人类大脑中,DHEA向其他代谢产物的代谢过程仍知之甚少,尤其是在老年人和阿尔茨海默病患者中。本研究首次描述了与非痴呆对照相比,阿尔茨海默病患者衰老大脑中DHEA体外转化为7α-羟基-DHEA和Δ5-雄烯-3β,17β-二醇的情况。通过气相色谱-质谱法对DHEA代谢产物进行了正式鉴定,从而表明存在NADPH依赖性7α-羟化酶和17β-羟基类固醇氧化还原酶活性。在我们的实验条件下,7α-羟基-DHEA和Δ5-雄烯-3β,17β-二醇的合成发生在阿尔茨海默病患者和非痴呆对照的额叶皮质、海马体、杏仁核、小脑和纹状体中。在两组患者中,DHEA的代谢模式相似,但与其他脑区相比,额叶皮质中7α-羟基-DHEA以及小脑和纹状体中Δ5-雄烯-3β,17β-二醇的合成显著更高。此外,发现皮质淀粉样沉积物密度与额叶皮质中形成的7α-羟基-DHEA量以及海马体中Δ5-雄烯-3β,17β-二醇量之间存在显著负相关趋势。因此,7α-羟基-DHEA和/或Δ5-雄烯-3β,17β-二醇的生物合成可能调节大脑中DHEA的浓度,并可能有助于控制衰老大脑(包括阿尔茨海默病大脑)中DHEA的活性。